Bio-Pharma Opportunity: India's MedTech Meet Eyes $600B Global Pie

For biotech and pharmaceutical executives, the medical device space is a natural extension—from diagnostic reagents to AI-powered imaging and wearables. With the Indian government now making a deliberate pivot to domestic manufacturing, bio-pharma companies can leverage their existing R&D and quality infrastructure to capture a share of the $600 billion global market while reducing import dependency.

The 9th India Medical Device 2026 conference opened on August 7, 2026, at Vigyan Bhawan in New Delhi, signaling a concerted push by the Indian government and industry to transform the country into a global hub for medical device manufacturing. Organized by the Department of Pharmaceuticals and the Federation of Indian Chambers of Commerce and Industry (FICCI), the two-day event convened policymakers, regulators, innovators, and business leaders under the theme ‘Towards Viksit Bharat: Advancing India as a Global Hub for Quality Medical Devices’.

“

Manoj Joshi, Secretary of the Department of Pharmaceuticals, highlighted that India’s medical device market currently stands at $16 billion, a fraction of the $600 billion global market.

The inaugural session laid out the scale of the opportunity. Manoj Joshi, Secretary of the Department of Pharmaceuticals, highlighted that India’s medical device market currently stands at $16 billion, a fraction of the $600 billion global market. He emphasized that the sector must be viewed through both a healthcare and an industry lens: while healthcare providers prioritize access to quality devices regardless of provenance, domestic manufacturing is essential for employment, industrial capability, and supply-chain resilience—lessons underscored by recent global disruptions. This dual framing reflects a maturation in Indian policy thinking, acknowledging that import dependence not only strains healthcare budgets but also exposes the country to strategic vulnerabilities.

Joshi noted tangible progress in local production, particularly in consumables, disposables, and the assembly of high-end equipment such as diagnostics and imaging systems. However, he stressed the need to deepen domestic value addition by strengthening component manufacturing, encouraging innovation in advanced medical technologies, and continuously raising quality standards. These remarks signal a shift from simple assembly operations to a more integrated, R&D-intensive ecosystem.

The regulatory dimension was addressed by Rajeev Singh Raghuvanshi, the Drug Controller General of India (DCGI), who called for a transformation from an import-driven model to one led by domestic manufacturing. Such statements from the country’s top devices regulator indicate that future policy may include streamlined approvals, quality benchmarks aligned with international norms, and production-linked incentive schemes that have already proven effective in other sectors. For industry participants, this would reduce uncertainty and unlock investment.

A white paper on strengthening medical equipment service and maintenance was released during the inaugural session. This often-overlooked aspect of the device lifecycle is critical for both patient safety and total cost of ownership. By addressing after-sales support, the government acknowledges that lowering dependency on foreign original equipment manufacturers for maintenance can further boost confidence in locally produced devices and make them more attractive to both domestic and export markets.

The conference theme aligns with India’s broader ambition of becoming a developed nation by 2047 (‘Viksit Bharat’). The medical device sector is seen as a high-growth, high-value industry that can create jobs, reduce the trade deficit in healthcare products, and position India as a reliable alternative to China in global supply chains. With the world’s second-largest population and a growing middle class, the domestic market alone provides a testing ground for scale, while exports to other emerging economies in Asia, Africa, and Latin America represent a sizable opportunity.